Project Grant R43HL180057
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $418K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lynn, MA 01904, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Berendo Scientific LLC $583,718 in project grant funding on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize and evaluate the SLEEPFLEX head and neck exercise program for treating mild to moderate obstructive sleep apnea. The recipient will develop a non-invasive treatment delivering targeted head and neck exercises via smartphone application (iOS and Android) with instructional videos and...
- The National Heart, Lung, and Blood Institute awarded Vivamed, Inc. $257,015 on June 15, 2026, to develop a wirelessly powered, battery-free hypoglossal nerve stimulator for treating obstructive sleep apnea under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of a minimally invasive implantable device designed to address limitations of existing hypoglossal nerve stimulation systems. The device will integrate electromyography sensors for real-time muscle...
- The National Heart, Lung, and Blood Institute awarded $920,616 to Vena Vitals Inc. on September 24, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop VeriSleep, a wearable device for continuous, non-invasive blood pressure monitoring during sleep as a cardiovascular biomarker. The project addresses the technological gap in continuous blood pressure measurement during sleep, where current intermittent cuff-based monitors leave lengthy unmonitored gaps despite the...
- The National Heart, Lung, and Blood Institute awarded $316,609 to Remplenish, Inc. on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel myofunctional nipple device for preventing obstructive sleep apnea in infants. The recipient will design and validate a low-risk, low-burden device that delivers myofunctional therapy—oropharyngeal exercises integrated into infant bottle feeding—as a non-invasive first-line treatment and preventive measure...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $1.542 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to improve understanding of sleep apnea pathogenesis using novel imaging techniques during sleep. The research combines drug-induced sleep endoscopy (DISE) with dynamic magnetic resonance imaging (MRI) to characterize upper airway anatomy and the mechanisms of airway collapse during sleep. The...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $492,250 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct data-driven phenotyping of obstructive sleep apnea and sex-specific cardiovascular consequences. The research integrates high-dimensional physiological and clinical data from the Mass General Brigham Health System electronic health record cohort, which includes over 144,000 patients with structured records...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $894,690 on July 3, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanisms of hypoglossal nerve stimulation (HGNS) failure in obstructive sleep apnea treatment. The research examines laterally directed pharyngeal collapse as the anatomical cause underlying HGNS therapy failure. Current HGNS screening relies on drug-induced sleep endoscopy (DISE), an invasive...
- The National Heart, Lung, and Blood Institute awarded Nightingale Labs Corp $1.368 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to commercialize non-contact cardiopulmonary monitoring technology for heart failure management. Nightingale Labs is developing a fully automated, non-contact home bed sensor platform that monitors cardiopulmonary physiology without requiring active patient participation, aimed at detecting clinical deterioration in heart...
- The National Science Foundation awarded a $256,000 Small Business Innovation Research Phase I Project Grant to Lumostech, Inc. under the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a smart sleep mask and mobile application to improve sleep for adolescents. The one-year project will apply light flash technology delivered through a sleep mask to advance teenagers' circadian phases without disrupting daytime activities. Cognitive behavioral therapy delivered via mobile...
- The National Heart, Lung, and Blood Institute awarded Acouflow Therapeutics LLC $497,857 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish the safety, preliminary efficacy, and commercial readiness of VortexPAP, a novel positive airway pressure therapy device for treating mild to moderate obstructive sleep apnea without a sealed mask. The project addresses poor patient adherence to conventional CPAP therapy by leveraging vortical airflow to...